Alvaro Ingles Garces
Overview
Explore the profile of Alvaro Ingles Garces including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
74
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Banerjee S, Michalarea V, Ang J, Ingles Garces A, Biondo A, Funingana I, et al.
Clin Cancer Res
. 2022 Aug;
28(21):4634-4641.
PMID: 35984704
Purpose: CT900 is a novel small molecule thymidylate synthase inhibitor that binds to α-folate receptor (α-FR) and thus is selectively taken up by α-FR-overexpressing tumors. Patients And Methods: A 3+3...
2.
Mason R, Au L, Ingles Garces A, Larkin J
Expert Opin Pharmacother
. 2019 Apr;
20(9):1135-1152.
PMID: 31025594
Introduction: Melanoma therapies have evolved rapidly, and initial successes have translated into survival gains for patients with advanced melanoma. Both targeted and immune-therapy now have evidence in earlier stage disease....
3.
Michalarea V, Fontana E, Ingles Garces A, Williams A, Smyth E, Picchia S, et al.
Curr Probl Cancer
. 2019 Mar;
43(5):487-494.
PMID: 30827742
Gastrointestinal cancers are very common cancers with colorectal being the fourth most common type, gastric the sixth, and esophageal the tenth. Although recent advances have been made in management including...
4.
Ameratunga M, Chenard-Poirier M, Candilejo I, Pedregal M, Lui A, Dolling D, et al.
Eur J Cancer
. 2017 Dec;
89:56-63.
PMID: 29227818
Background: Although the neutrophil-lymphocyte ratio (NLR) is prognostic in many oncological settings, its significance in the immunotherapy era is unknown. Mechanistically, PD-1/PD-L1 inhibitors may alter NLR. We sought to characterise...